Predictors for Side Branch Failure During Provisional Strategy of Coronary Intervention for Bifurcation Lesions (from the Korean Bifurcation Registry)

Am J Cardiol. 2016 Sep 15;118(6):797-803. doi: 10.1016/j.amjcard.2016.06.049. Epub 2016 Jun 28.

Abstract

The most favored strategy for bifurcation lesion is stenting main vessel with provisional side branch (SB) stenting. This study was performed to elucidate predictors for SB failure during this provisional strategy. The study population was patients from 16 centers in Korea who underwent drug-eluting stent implantation for bifurcation lesions with provisional strategy (1,219 patients and 1,236 lesions). On multivariate analysis, the independent predictors for SB jailing after main vessel stenting were SB calcification, large SB reference diameter, severe stenosis of SB, and not taking clopidogrel. Regarding SB compromise, however, the independent predictors were true bifurcation lesion and small SB reference diameter, whereas possible predictors were parent vessel thrombus and parent vessel total occlusion. In addition, SB predilation helps us to get favorable SB outcome. The diameter of SB ostium after main vessel stenting became similar between severe SB lesions treated with predilation and mild SB lesions not treated with predilation. In conclusion, SB calcification, less clopidogrel use, large SB reference diameter, and high SB diameter stenosis are independent predictors for SB jailing, and true bifurcation and small SB reference diameter are independent predictors for SB compromise after main vessel stenting.

MeSH terms

  • Aged
  • Calcinosis / epidemiology
  • Clopidogrel
  • Coronary Angiography
  • Coronary Artery Disease / epidemiology
  • Coronary Stenosis / epidemiology
  • Coronary Stenosis / surgery*
  • Coronary Vessels / diagnostic imaging
  • Coronary Vessels / pathology
  • Coronary Vessels / surgery
  • Drug-Eluting Stents*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Organ Size
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prognosis
  • Registries*
  • Republic of Korea / epidemiology
  • Risk Factors
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / therapeutic use
  • Treatment Failure

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine